ACST Stock – (NASDAQ: ACST) is actually providing an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the use of the “at the market” equity of its providing program.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering program under which Acasti may issue as well as sell from time to time its everyday shares having an aggregate offering price of up to $75 million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January 27, 2021, Acasti granted an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 million. The ATM Shares had been marketed at prevailing market rates averaging US$1.0747 a share. No securities were offered through the facilities of the TSXV or perhaps, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with the services of theirs. As a result of the latest ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March 5, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and will supply the Company with extra flexibility in its continuous review process to enjoy as well as evaluate strategic alternatives.
Approximately Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescription drugs using OM3 fatty acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical proof of efficacy and safety in lowering triglycerides in clients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for people with serious HTG.
Forward Looking Statements – ACST Stock
Statements in that press release which aren’t statements of historical or current fact constitute “forward-looking information” to the meaning of Canadian securities laws as well as “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking statements include known and unknown risks, uncertainties, as well as other unknown elements that might cause the actual results of Acasti to be materially different from historical outcomes and even from any later outcomes expressed or even implied by such forward looking statements. In addition to statements which explicitly describe such risks as well as uncertainties, people are urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other related expressions to be forward-looking and uncertain. People are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the date of this particular press release. Forward-looking statements in that press release include, but aren’t confined to, statements or information about Acasti’s strategy, succeeding operations and the review of its of strategic options.
The forward looking assertions found in this specific press release are expressly qualified in the entirety of theirs by this cautionary statement, the “Special Note Regarding Forward Looking Statements” section found in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor section of Acasti’s website at www.acastipharma.com. Many forward-looking assertions in this press release are manufactured as of the particular date of this particular press release.
ACST Stock – Acasti doesn’t undertake to redesign some such forward-looking statements whether as a result of brand new info, future events or perhaps otherwise, except as called for by law. The forward looking statements contained herein are also subject typically to risks and assumptions and uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the use